Ardent Health: The Market Is Still Pricing the Q3 Loss While Free Cash Flow Nearly Doubled

Ardent Health (ARDT) reports second-quarter results after the close today. The stock is trading around $10.60, well below its 52-week high of $15.48 and sitting below book value. If you follow the headlines, you'd think this is still a cost-constrained operator stumbling through industry headwinds. If you follow the cash-flow path, the story is already bending the other way.

The old story

The bear case was built on two quarters. In Q3 2025, Ardent posted a $23 million net loss - $0.17 per share - on a mix of accelerating professional fees (up 11% that quarter), worsening payor denials, and a $43 million revenue write-down from a change in accounting methodology for estimating accounts receivable collectability. Then Q4 2025 missed on revenue, though EPS of $0.32 beat the consensus estimate. The stock fell sharply off those results.

That narrative had one job: convince investors that Ardent's margin profile was structurally deteriorating and that industry cost pressures would only get worse. The Q4 miss and cautious 2026 guidance locked the discount in.

The proof path

Free cash flow is the one number that doesn't care about the narrative. Trailing-twelve-month free cash flow - cash from operations minus capital expenditures, the actual cash the business generates for debt service, reinvestment, or returning to shareholders - sits at $218 million. That is up 84% year-over-year.

Operating cash flow for the full year 2025 was $471 million, nearly 50% higher than 2024. In Q4 2025 alone, operating cash flow was $223 million, up 87% year-over-year. The company carried over $700 million in cash at year-end and brought net leverage down to 2.5x.

Then came Q1 2026. Revenue hit $1.60 billion, up 7% year-over-year. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization, a rough cash-earnings proxy that management uses to track operating performance) grew 26.3% to $124 million. GAAP EPS of $0.28 beat the consensus estimate of $0.19. Adjusted admissions grew 2%, surgeries turned positive at 1.2% growth, and the IMPACT cost-reduction program - management's multi-pronged effort targeting supply chain, staffing precision, and operating room efficiency - was already delivering savings.

Management is now targeting $55 million in IMPACT savings for 2026, up from the $40 million previously guided. Supplemental workforce expenses, particularly contract labor, improved for two consecutive quarters. Payor denial trends stabilized.

Why the market hasn't moved on

The stock trades at 6.7 times forward earnings and 0.88 times book value. EV/EBITDA is 4.6x. That is not just cheap for Ardent; it's cheap for any operator growing free cash flow at 84%.

The market is still anchored to the Q3 loss and the cautious 2026 guidance. Full-year 2026 adjusted EBITDA guidance of $485-$535 million represents a decline of roughly 6% at the midpoint versus 2025's actual $545 million. Management themselves set a low bar, explicitly flagging ongoing professional fee pressure and the expiration of enhanced Exchange subsidies as headwinds. The guidance was deliberately conservative.

But the guided decline for 2026 is the bridge, not the destination. Management said on the Q4 call that 2027 is when adjusted EBITDA growth returns. They also said the business is well-positioned with durable demand, IMPACT-driven efficiencies, and a strong balance sheet. The 2026 guided decline is the annualization of headwinds that are already moderating on a quarter-by-quarter basis. Q1 adjusted EBITDA grew 26%. If Q2 follows that cadence, the full-year midpoint of their guidance starts looking conservative by year-end.

For-profit health systems broadly outperformed the healthcare sector in 2025. The for-profits proved nimbler on cost management, more aggressive on AI-enabled revenue cycle tools, and better positioned on outpatient demand. Ardent is part of that cohort, but its valuation still reflects the hospital of the past.

What Q2 tells us

Consensus expects $0.18 EPS and roughly $1.59 billion in revenue. The actual numbers matter less than three directional checks:

• Professional fees: Were they managed in line with management's renegotiated contracts, or did they accelerate again like Q3 2025? This is the single biggest margin risk. Professional fees - payments to physicians and clinical specialists for their services, separate from the facility fee the hospital charges - grew 8% in Q4 2025. Any sign that's moderating further validates the IMPACT program.
• Admissions and surgeries: Q1 showed adjusted admissions up 2% and surgeries up 1.2%. Continued volume growth across both metrics would signal that demand remains durable and that the severe-weather and light-respiratory-season headwinds from Q1 don't repeat.
• Cash conversion: Q4 was $223M in operating cash flow. Even half that in Q2 would keep the trailing FCF trajectory intact. Management mentioned a $10.9 million investment gain in Q1 - investors will want to see that operating cash flow is the engine, not one-off items.

The setup

The financial bridge is simple. If FY2026 hits the midpoint of guidance at roughly $510 million in adjusted EBITDA, and FY2027 returns to mid-to-high single-digit adjusted EBITDA growth as management has signaled, the operator is adding roughly $30-50 million in incremental cash earnings. On the current share count, that translates to material GAAP earnings growth in 2027.

The stock at 6.7x forward earnings assumes nothing improves. A re-rating to a 12x multiple - still well below the 15x-20x range for faster-growing peers like HCA - would imply a share price in the $18-20 range. That's the kind of asymmetric move you get when the market is pricing last year's problems.

Target, timeframe, tripwire

• Target: $18-20 over 12-18 months, through the publication of 2027 results.
• Timeframe: Mid-2027 to early 2028.
• Tripwire: If Q2 or Q3 shows professional fees re-accelerating above double digits, admissions turning negative, or operating cash flow declining materially from the Q4 pace, the cost-structure thesis is back in play. Cut without hesitation. Discipline over ego.

The market is still pricing the old risk profile while the operating setup is already getting cleaner. This is not about excitement. It is about a business that may soon look a lot harder to dismiss once the free cash flow keeps showing up and the multiple catches the reality of what it's buying.